

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 February 2022 (24.02.2022)



(10) International Publication Number
WO 2022/040560 A1

- (51) **International Patent Classification:**
A61P 19/08 (2006.01) *C07K 16/28* (2006.01)
- (21) **International Application Number:**
PCT/US2021/046958
- (22) **International Filing Date:**
20 August 2021 (20.08.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/068,575 21 August 2020 (21.08.2020) US
- (71) **Applicant: GENZYME CORPORATION** [US/US]; 50 Binney Street, Cambridge, Massachusetts 02142 (US).
- (72) **Inventors: SABBAGH, Yves;** c/o Genzyme Corporation, 50 Binney Street, Cambridge, Massachusetts 02142 (US). **CHEN, Yangde;** c/o Genzyme Corporation, 50 Binney Street, Cambridge, Massachusetts 02142 (US). **BRONDYK, William;** c/o Genzyme Corporation, 50 Binney Street, Cambridge, Massachusetts 02142 (US). **QIU, Huawei;** c/o Genzyme Corporation, 50 Binney Street, Cambridge, Massachusetts 02142 (US). **PARK, Sunghae;** c/o Genzyme Corporation, 50 Binney Street, Cambridge, Massachusetts 02142 (US). **WEI, Ronnie;** c/o Genzyme Corporation, 50 Binney Street, Cambridge, Massachusetts 02142 (US). **QIU, Yu;** c/o Genzyme Corporation, 50 Binney Street, Cambridge, Massachusetts 02142 (US). **ZHOU, Yanfeng;** c/o Genzyme Corporation, 50 Binney Street, Cambridge, Massachusetts 02142 (US). **LEMOINE, Cen-**

drine; c/o Genzyme Corporation, 50 Binney Street, Cambridge, Massachusetts 02142 (US). **CHO, HyunSuk;** c/o Genzyme Corporation, 50 Binney Street, Cambridge, Massachusetts 02142 (US).

(74) **Agent: VELEMA, James H.** et al.; LATHROP GPM, 28 State Street, Boston, Massachusetts 02109 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title: FGFR3 ANTIBODIES AND METHODS OF USE**




FIG. 1

(57) **Abstract:** Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))